VASCO study (Vaccine Study COvid-19)

VASCO study: A population-based prospective cohort study on vaccine effectiveness of COVID-19 vaccines in the Netherlands

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON26317

Enrollment

50000

Registered

2021-02-17

Start date

2021-03-01

Completion date

Unknown

Last updated

2024-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Covid-19

Interventions

No intervention

Eligibility

Inclusion criteria

Inclusion criteria: - Community dwelling adult between 18-79 years - Informed consent provided - Be able to read, understand and write Dutch

Exclusion criteria

Exclusion criteria: - Not able or willing to understand and sign the informed consent - Not able to fill out a digital (app) questionnaire - Persons living in an institution (e.g. elderly care home, nursing home)

Design outcomes

Primary

Measure	Time frame
The primary endpoint is time to first symptomatic SARS-CoV-2 infection, determined by a positive PCR or antigen test in combination with COVID-19 related symptoms. Those infections can be detected through the national testing programme.	—

Secondary

Measure	Time frame
Secondary endpoints that will be investigated: - SARS-CoV-2 infections by disease severity: COVID-19 related death, COVID-19 related hospitalization, mild SARS-CoV-2 infection, asymptomatic SARS-CoV-2 infection - Unsolicited adverse events for which medical attention was sought	—

Contacts

Public ContactMaartje Hoffmann

Julius Clinical

regulatory@juliusclinical.com+31306569900

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)